Literature DB >> 19699688

Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss.

Lucia S Graham1, Farhad Parhami, Yin Tintut, Christina M R Kitchen, Linda L Demer, Rita B Effros.   

Abstract

Osteoporosis is a systemic disease that is associated with increased morbidity, mortality and health care costs. Whereas osteoclasts and osteoblasts are the main regulators of bone homeostasis, recent studies underscore a key role for the immune system, particularly via activation-induced T lymphocyte production of receptor activator of NFkappaB ligand (RANKL). Well-documented as a mediator of T lymphocyte/dendritic cell interactions, RANKL also stimulates the maturation and activation of bone-resorbing osteoclasts. Given that lipid oxidation products mediate inflammatory and metabolic disorders such as osteoporosis and atherosclerosis, and since oxidized lipids affect several T lymphocyte functions, we hypothesized that RANKL production might also be subject to modulation by oxidized lipids. Here, we show that short term exposure of both unstimulated and activated human T lymphocytes to minimally oxidized low density lipoprotein (LDL), but not native LDL, significantly enhances RANKL production and promotes expression of the lectin-like oxidized LDL receptor-1 (LOX-1). The effect, which is also observed with 8-iso-Prostaglandin E2, an inflammatory isoprostane produced by lipid peroxidation, is mediated via the NFkappaB pathway, and involves increased RANKL mRNA expression. The link between oxidized lipids and T lymphocytes is further reinforced by analysis of hyperlipidemic mice, in which bone loss is associated with increased RANKL mRNA in T lymphocytes and elevated RANKL serum levels. Our results suggest a novel pathway by which T lymphocytes contribute to bone changes, namely, via oxidized lipid enhancement of RANKL production. These findings may help elucidate clinical associations between cardiovascular disease and decreased bone mass, and may also lead to new immune-based approaches to osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699688      PMCID: PMC2805272          DOI: 10.1016/j.clim.2009.07.011

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  78 in total

1.  TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.

Authors:  B R Wong; J Rho; J Arron; E Robinson; J Orlinick; M Chao; S Kalachikov; E Cayani; F S Bartlett; W N Frankel; S Y Lee; Y Choi
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

2.  Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.

Authors:  T Q Callister; P Raggi; B Cooil; N J Lippolis; D J Russo
Journal:  N Engl J Med       Date:  1998-12-31       Impact factor: 91.245

3.  Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha.

Authors:  H Moriwaki; N Kume; H Kataoka; T Murase; E Nishi; T Sawamura; T Masaki; T Kita
Journal:  FEBS Lett       Date:  1998-11-27       Impact factor: 4.124

Review 4.  Low density lipoprotein oxidation and its pathobiological significance.

Authors:  D Steinberg
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

5.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

6.  Bone changes and carotid atherosclerosis in postmenopausal women.

Authors:  O Uyama; Y Yoshimoto; Y Yamamoto; A Kawai
Journal:  Stroke       Date:  1997-09       Impact factor: 7.914

7.  The association between low bone mass at the menopause and cardiovascular mortality.

Authors:  P von der Recke; M A Hansen; C Hassager
Journal:  Am J Med       Date:  1999-03       Impact factor: 4.965

8.  Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women.

Authors:  E I Barengolts; M Berman; S C Kukreja; T Kouznetsova; C Lin; E V Chomka
Journal:  Calcif Tissue Int       Date:  1998-03       Impact factor: 4.333

9.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes.

Authors:  S Caspar-Bauguil; J Tkaczuk; M J Haure; M Durand; J Alcouffe; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

View more
  34 in total

1.  Editorial: T cell memory, bone marrow, and aging: the good news.

Authors:  Rita B Effros
Journal:  J Leukoc Biol       Date:  2012-02       Impact factor: 4.962

Review 2.  The bone-vascular axis in chronic kidney disease.

Authors:  Linda Demer; Yin Tintut
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-07       Impact factor: 2.894

3.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

Review 4.  The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification.

Authors:  Linda Demer; Yin Tintut
Journal:  Circ Res       Date:  2011-06-10       Impact factor: 17.367

5.  Human immune compartment comparisons: Optimization of proliferative assays for blood and gut T lymphocytes.

Authors:  Jeffrey Dock; Lance Hultin; Patricia Hultin; Julie Elliot; Otto O Yang; Peter A Anton; Beth D Jamieson; Rita B Effros
Journal:  J Immunol Methods       Date:  2017-03-21       Impact factor: 2.303

Review 6.  Functional impairment of bone formation in the pathogenesis of osteoporosis: the bone marrow regenerative competence.

Authors:  Joseph P Bidwell; Marta B Alvarez; Mark Hood; Paul Childress
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

7.  Plasma phosphatidylcholine concentrations of polyunsaturated fatty acids are differentially associated with hip bone mineral density and hip fracture in older adults: the Framingham Osteoporosis Study.

Authors:  Emily K Farina; Douglas P Kiel; Ronenn Roubenoff; Ernst J Schaefer; L Adrienne Cupples; Katherine L Tucker
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

Review 8.  Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress.

Authors:  Rita B Effros
Journal:  Exp Gerontol       Date:  2010-09-15       Impact factor: 4.032

9.  Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis.

Authors:  Jennifer M P Woo; Zhuofeng Lin; Mohamad Navab; Casey Van Dyck; Yvette Trejo-Lopez; Krystal M T Woo; Hongyun Li; Lawrence W Castellani; Xuping Wang; Noriko Iikuni; Ornella J Rullo; Hui Wu; Antonio La Cava; Alan M Fogelman; Aldons J Lusis; Betty P Tsao
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

10.  Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection.

Authors:  Theodoros Kelesidis; Nicholas Jackson; Grace A McComsey; Xiaoyan Wang; David Elashoff; Michael P Dube; Todd T Brown; Otto O Yang; James H Stein; Judith S Currier
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.